United Therapeutics Corporation
United Therapeutics Announces Positive Results for Tyvaso in Treating IPF
Summary
On September 2, 2025, United Therapeutics Corporation announced positive results from the TETON-2 clinical study for Tyvaso (treprostinil) Inhalation Solution in treating idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint, showing significant improvement in absolute forced vital capacity (FVC) compared to placebo, with benefits observed across all subgroups. The results also indicated improvements in several key secondary endpoints, including time to first clinical worsening event, and changes in quality of life and lung function. The company plans to use these results to support a supplemental New Drug Application to the FDA for IPF treatment. The safety profile was consistent with previous studies.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement